View in EDS

Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.

Saved in:
Bibliographic Details
Title: Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
Authors: Shah A; Modelling and Simulation, Evidera, Waltham, MA, USA., Tosh JC; Modelling and Simulation, Evidera, London, UK., Ambavane A; Modelling and Simulation, Evidera, London, UK., Nikolaou A; Modelling and Simulation, Evidera, London, UK., Hogea C; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA., Samyshkin Y; Value Evidence and Outcomes, GlaxoSmithKline, Brentford, UK., Gorsh B; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA., Maiese EM; Value Evidence and Outcomes, GlaxoSmithKline, Philadelphia, PA, USA., Wang F; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA.
Source: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2021 Sep 10; Vol. 13, pp. 789-800. Date of Electronic Publication: 2021 Sep 10 (Print Publication: 2021).
Publication Type: Journal Article
Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101560564 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6981 (Print) Linking ISSN: 11786981 NLM ISO Abbreviation: Clinicoecon Outcomes Res Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34531667
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shah+A%22">Shah A</searchLink>; Modelling and Simulation, Evidera, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tosh+JC%22">Tosh JC</searchLink>; Modelling and Simulation, Evidera, London, UK.<br /><searchLink fieldCode="AU" term="%22Ambavane+A%22">Ambavane A</searchLink>; Modelling and Simulation, Evidera, London, UK.<br /><searchLink fieldCode="AU" term="%22Nikolaou+A%22">Nikolaou A</searchLink>; Modelling and Simulation, Evidera, London, UK.<br /><searchLink fieldCode="AU" term="%22Hogea+C%22">Hogea C</searchLink>; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Samyshkin+Y%22">Samyshkin Y</searchLink>; Value Evidence and Outcomes, GlaxoSmithKline, Brentford, UK.<br /><searchLink fieldCode="AU" term="%22Gorsh+B%22">Gorsh B</searchLink>; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Maiese+EM%22">Maiese EM</searchLink>; Value Evidence and Outcomes, GlaxoSmithKline, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+F%22">Wang F</searchLink>; Value Evidence and Outcomes, GlaxoSmithKline, Upper Providence, PA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560564%22">ClinicoEconomics and outcomes research : CEOR</searchLink> [Clinicoecon Outcomes Res] 2021 Sep 10; Vol. 13, pp. 789-800. <i>Date of Electronic Publication: </i>2021 Sep 10 (<i>Print Publication: </i>2021).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Dove+Medical+Press%22">Dove Medical Press </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>101560564 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1178-6981 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211786981%22">11786981 </searchLink><i>NLM ISO Abbreviation: </i>Clinicoecon Outcomes Res <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34531667
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.2147/CEOR.S310619
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 789
    Titles:
      – TitleFull: Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shah A
      – PersonEntity:
          Name:
            NameFull: Tosh JC
      – PersonEntity:
          Name:
            NameFull: Ambavane A
      – PersonEntity:
          Name:
            NameFull: Nikolaou A
      – PersonEntity:
          Name:
            NameFull: Hogea C
      – PersonEntity:
          Name:
            NameFull: Samyshkin Y
      – PersonEntity:
          Name:
            NameFull: Gorsh B
      – PersonEntity:
          Name:
            NameFull: Maiese EM
      – PersonEntity:
          Name:
            NameFull: Wang F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 09
              Text: 2021 Sep 10
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 1178-6981
          Numbering:
            – Type: volume
              Value: 13
          Titles:
            – TitleFull: ClinicoEconomics and outcomes research : CEOR
              Type: main
ResultId 1